Is Hologic, Inc. overvalued or undervalued?

As of 17 October 2025, Hologic, Inc. has moved from an expensive to a fair valuation grade. The company appears fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65, which suggest that the stock is reasonably priced relative to its earnings growth potential.
In comparison to its peers, Hologic's P/E ratio of 21.83 is lower than Baxter International, Inc.'s risky valuation at 28.68 but higher than Align Technology, Inc.'s attractive valuation at 20.46. Additionally, Hologic's EV to EBITDA ratio is competitive within the industry, indicating a solid valuation position. Over the past year, Hologic's stock has underperformed against the S&P 500, returning -13.20% compared to the index's 14.08%, which may reflect market sentiment towards the stock despite its fair valuation.